Evaluation of the Recommended Dose and Efficacy of Amrubicin as Second- and Third-Line Chemotherapy for Small Cell Lung Cancer  by Igawa, Satoshi et al.
ORIGINAL ARTICLE
Evaluation of the Recommended Dose and Efficacy of
Amrubicin as Second- and Third-Line Chemotherapy
for Small Cell Lung Cancer
Satoshi Igawa, MD, PhD,* Nobuyuki Yamamoto, MD, PhD,* Shinya Ueda, MD,*‡ Akira Ono, MD,*
Yukiko Nakamura, MD,* Asuka Tsuya, MD,* Haruyasu Murakami, MD, PhD,*
Masahiro Endo, MD,† and Toshiaki Takahashi, MD, PhD*
Introduction: This study was conducted to evaluate the recom-
mended dose and activity of amrubicin (AMR) as second- or
third-line chemotherapy for small-cell lung cancer (SCLC).
Methods: Small-cell lung cancer patients with measurable disease
who had previously been treated with at least one platinum-based
chemotherapy regimen and had an Eastern Cooperative Oncology
Group performance status of 0–2 were eligible. Two groups of
patients were selected: (1) a group to be treated with second-line
chemotherapy and (2) a group to be treated with third-line chemo-
therapy. AMR was administered to both groups as a 5-minute daily
intravenous injection at a dose of 40 or 35 mg/m2 for three consec-
utive days every 3 weeks.
Results: Between March 2003 and June 2006, 27 patients (second-
line, 40 mg/m2: 13 patients; third-line, 40 mg/m2: seven patients;
and 35 mg/m2: seven patients) were enrolled. Although the 40-
mg/m2 dose of AMR was feasible (one of 13 patients developed
febrile neutropenia and four of 13 patients had grade 4 neutropenia)
and effective (six of 13 patients had a partial response) in the
second-line group, it produced unacceptable toxicity in a third-line
setting (three of seven patients with grade 3 nonhematologic toxic-
ities [febrile neutropenia in two patients and fatigue in one patient]
and four of seven patients with grade 4 neutropenia). The 35-mg/m2
dose of AMR had acceptable toxicity in the third-line group (one of
seven patients with febrile neutropenia and one of seven had grade
4 neutropenia) and moderate efficacy (one of seven patients had a
partial response and two of seven had stable disease).
Conclusions: AMR exhibits significant activity as second-line or
third-line chemotherapy for small-cell lung cancer. The recom-
mended dose is 40 mg/m2 in a second-line setting and 35 mg/m2 in
a third-line setting.
(J Thorac Oncol. 2007;2: 741–744)
Approximately 15% of lung cancer patients have small-celllung cancer (SCLC). Unlike other types of lung cancer,
SCLC is one of the most chemosensitive solid tumors.1 How-
ever, after remarkably successful induction therapy, most pa-
tients have a relapse within 2 years as a result of the emergence
of drug-resistant tumor cells. Thus, long-term survival is ex-
tremely uncommon, and less than 25% of patients with limited-
stage disease and less than 2% of patients with extensive-stage
disease remain alive at 5 years.2–4 The results of second-line
chemotherapy against SCLC are quite disappointing, with rela-
tively low response rates, brief remissions, and a short survival
time. A new effective agent is needed to achieve better treatment
results in patients with recurring or refractory SCLC.
Amrubicin hydrochloride is a totally synthetic 9-ami-
noanthracycline that is metabolically activated to amrubicinol
by a liver enzyme. Amrubicin and amrubicinol inhibit DNA
topoisomerase II and exert a cytotoxic effect by stabilizing a
topoisomerase II–mediated cleavable complex. They are ap-
proximately one tenth weaker than doxorubicin as a DNA
intercalator.5,6 The catatonic activity of amrubicinol in vitro is
18 to 220 times more potent than that of its parent compound,
amrubicin.7
Amrubicin has been reported to have shown more
potent antitumor activity than the representative anthracy-
cline doxorubicin in several human tumor xenografts im-
planted in nude mice and to have produced almost no car-
diotoxicity.8,9 Amrubicin at 45 mg/m2 on days 1 to 3 every 3
weeks has been shown to be active against previously un-
treated SCLC, with an overall response rate of 78.8% and a
median survival time (MST) of 11.0 months.10 Onoda et al.11
found that amrubicin 40 mg/m2 had significant activity and
acceptable toxicity in previously treated patients. However,
Kato et al.12 reported finding that amrubicin at 45 mg/m2 not
only had promising activity but severe and unacceptable
toxicity in patients, similar to those in the Onoda et al. study.
Most patients enrolled in both studies received amrubicin as
second-line treatment.
Accordingly, the results of the previous studies are of
value in considering amrubicin as a key agent for the treat-
ment of SCLC, not only untreated cases but in previously
treated cases. However, the recommended dose for previ-
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ously treated patients has not been determined, especially in
third-line or greater settings.
The purpose of this study was to evaluate the toxicity
and efficacy of amrubicin as second- and third-line chemo-
therapy in SCLC patients in a clinical setting to determine the
recommended dose.
PATIENTS AND METHODS
Patient Selection
The subjects of this study were 27 patients with previ-
ously treated SCLC between March 2003 and June 2006 at
Shizuoka Cancer Center. The recruitment criteria were (1)
history of at least one platinum-based chemotherapy regimen
and confirmation of refractory or recurrent SCLC based on
the results of the following examinations: chest radiograph,
computed tomography of the chest and abdomen, and other
procedures as indicated, including magnetic resonance imag-
ing of the head and positron emission tomography or com-
bined positron emission tomography/computed tomography;
(2) age 75 years or younger; (3) performance status of 2 or
less according to the Eastern Cooperative Oncology Group
scale; (4) adequate bone marrow, hepatic, and renal function;
(5) no other serious disease; (6) written informed consent.
Treatment Methods
The treatment schedule comprised a 5-minute intrave-
nous infusion of amrubicin in 50 ml normal saline on days 1
to 3 every 3 weeks. Patients receiving second-line chemo-
therapy were treated with a dose of 40 mg/m2. The first seven
consecutive patients in the third-line group were treated with
a dose of 40 mg/m2, and the next seven patients were treated
with a dose of 35 mg/m2. Before the start of treatment, the
patient had to have an absolute neutrophil count of 1500/mm3
or more, a platelet count of 100,000/mm3 or more, aspartate
aminotransferase and alanine aminotransferase values less
than three times the maximum value in the normal range, and
total bilirubin and creatinine values less than 1.5 times the
maximum value in the normal range. Treatment with granu-
locyte colony-stimulating factor was permitted as a therapeu-
tic intervention but was not mandatory as a prophylactic
agent against neutropenia as hematologic toxicity. Subse-
quent doses were modified based on hematologic and nonhe-
matologic toxicities at the discretion of the physician in
charge. Complete blood count and biochemistry examina-
tions were repeated at least once per week after the initial
evaluation.
Evaluation of Response and Toxicity
Adverse events were recorded and graded using the
National Cancer Institute Common Toxicity Criteria, Version
3.0 grading system. Tumor response was classified in accor-
dance with the Response Evaluation Criteria in Solid Tumors.
Patients were evaluated to determine the stage of their disease
before treatment and when their disease progressed or re-
curred by taking a complete medical history and performing
a physical examination, chest radiography, computed tomog-
raphy of the chest and abdomen, and other staging proce-
dures, such as magnetic resonance imaging of the head, and
positron emission tomography.
Limited disease was defined as disease confined to one
hemithorax, including bilateral mediastinal and bilateral su-
praclavicular nodes, and extensive disease (ED) was defined
as any involvement beyond these confines. Primary refractory
disease was defined as recurrence during the first-line che-
motherapy regimen or less than 8 weeks after completing the
initial chemotherapy regimen, and sensitive disease was de-
fined as recurrence more than 8 weeks after completion of the
first-line chemotherapy.
Definition of Recommended Dose
The recommended dose of amrubicin was defined as the
dose at which severe toxicity occurred in less than 33% of the
patients treated. At least six patients were treated at each dose
level. Severe toxicity was defined as grade 4 hematologic
toxicity and grade 3 or higher nonhematologic toxicity in-
cluding febrile neutropenia.
Statistical Methods
Kaplan-Meier plots were prepared for overall survival,
and median values were calculated. Overall survival was
measured from the first day of amrubicin treatment to the day
of death or the day last seen alive (cutoff).
RESULTS
Patient Characteristics
Between March 2003 and June 2006, 27 patients with
recurring or refractory disease were enrolled in this study.
The characteristics of the patients are listed in Table 1. Four
patients were women and 23 were men, and the patients’
median age was 64 years (range, 53–74 years). At the start of
the treatment one patient had limited disease and 26 patients
had ED. All 27 patients had been treated with some form of
chemotherapeutic regimen: 13 had received one previous
regimen, 14 had received two previous regimens. All patients
had been previously treated with some form of cisplatin- (23
patients) or carboplatin-based combination chemotherapy; 19
patients had received an irinotecan-containing regimen and
one patient had received a topotecan-containing regimen.
TABLE 1. Patient Characteristics
Characteristic
Age, yr, median (range) 64 (53–74)
Gender: male/female 23/4
PS: 0/1/2 2/21/4
Stage: limited disease/extended disease 1/26
No. of previous chemotherapy regimens: 1/2 13/14
Amrubicin dose, days 1–3
Second-line: 40 mg/m2 13
Third-line: 40/35 mg/m2 7/7
Refractory/sensitive 8/19
PS, performance status.
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Toxicity
The toxicity of the regimen is summarized in Table 2.
Table 2 shows the worst toxicity level in each patient. Grade
4 neutropenia was observed in four (31%) of the 13 patients
receiving second-line chemotherapy with 40 mg/m2 of am-
rubicin, and four cases of grade 4 neutropenia (57%) and one
case of grade 3 (14%) were observed among the seven
patients receiving third-line chemotherapy. However, only
one of the seven third-line patients who received the reduced
dose of 35 mg/m2 developed grade 4 neutropenia (14%).
Febrile neutropenia was observed in one patient (8%) in the
second-line group who received 40 mg/m2, two patients
(28%) in the third-line group who received 40 mg/m2, and
one patient (14%) in the third-line group who received 35
mg/m2. All other hematologic toxicities were mild. Two
cases (28%) of grade 3 nonhematologic toxicities other than
febrile neutropenia were observed one in the second-line
group and the other in third-line group.
Accordingly, the recommended dose of amrubicin for
second-line treatment and third-line treatment was concluded
to be 40 mg/m2/day and 35 mg/m2/day, respectively.
Response and Survival
No complete responses and eight partial responses were
observed among the 27 patients (29%). A comparatively
high response rate was achieved in the second-line che-
motherapy group, with a response rate of 46% (six of 13
patients) in the group who received the 40-mg/m2 dose.
The patients in the third-line group who received the
40-mg/m2 dose and the 35-mg/m2 dose had a similar
response rate: 14% (one of seven patients). The sensitive
cases and refractory recurrence cases had response rates of
42% (3/7) and 25% (5/20), respectively. The overall me-
dian survival time (MST) and 1-year survival rate were 9.2
months and 33.3%, respectively (Figures 1 and 2).
DISCUSSION
The outlook for SCLC patients who receive second-line
chemotherapy has been poor, and few single agents have
been capable of producing a high response rate among pa-
tients with early recurrence or disease progression during
treatment. The new agents that have been most extensively
evaluated in SCLC are the topoisomerase I inhibitors irino-
tecan and topotecan. A recent randomized phase III trial
demonstrated that single-agent topotecan was at least as
effective as the three-drug combination of cyclophospha-
mide, doxorubicin, and vincristine in patients with disease
progression at least 60 days after initial therapy. Topotecan
yielded a response rate of 24.3% versus 18.3% for cyclophos-
phamide, doxorubicin, and vincristine, with an MST of 25.0
versus 24.7 weeks and improved symptom control.13 Two
studies of irinotecan in patients with refractory SCLC have
been reported in Japan, and the response rate in both studies
was high: 50% in 16 patients and 47% in 15 patients.14,15
Irinotecan and topotecan have been recognized as key drugs
in the second-line treatment of SCLC. A recent phase III
study that compared irinotecan plus cisplatin with etoposide
and cisplatin in patients with ED-SCLC revealed a superior
median survival rate and a superior 2-year survival rate for
the irinotecan plus cisplatin combination.16 As a result, iri-
notecan plus cisplatin was established as one of the standard
first-line regimens for SCLC in Japan. Thus, it has been
necessary to search for effective drugs other than the topo-
isomerase I inhibitors for previously treated SCLC.
A response rate of 79% has been reported for amrubicin
at a dose of 45 mg/m2 on days 1 to 3 in chemotherapy-naive
ED-SCLC patients in an intent-to-treat analysis.10 Because of
its very high activity as a single agent in untreated ED-SCLC
patients, amrubicin has since been approved for SCLC in
Japan in April 2002. Amrubicin has mainly been used for
previously treated SCLC in clinical practice because of the
higher response rate of untreated SCLC and an antitumor
mechanism that differs from that of platinum and topoisom-
erase I inhibitors.
However, the recommended dose of amrubicin for
previously treated SCLC was unknown.
The dose approved by the Japanese Ministry of Labor,
Health, and Welfare is 45 mg/m2 on days 1 to 3. Kato et al.12
conducted a phase II study of amrubicin 45 mg/m2 in previ-
TABLE 2. Toxicity by Dose
ANC Hb PLT
FN
G3
Other
G3Pts G3 G4 G3 G4 G4 G3
Second-line: 40 mg/m2 13 2 4 0 0 2 0 1 1 Dyspnea
Third-line: 40 mg/m2 7 0 4 1 0 2 1 2 1 Fatigue anorexia
Third-line: 35 mg/m2 7 5 1 1 0 3 0 1 0
Pts, patients; ANC, absolute neutrophil count; Hb, hemoglobin; PLT, ●●●; FN, febrile neutropenia; G, grade.
FIGURE 1. Kaplan-Meier plot of overall survival in all patients.
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ously treated SCLC patients, mostly second-line chemother-
apy patients, and reported severe hematologic toxicity and a
high incident of febrile neutropenia.
The incidence of severe amrubicin toxicity at the 40-
mg/m2 dose as second-line chemotherapy was 31% (four of
13: grade 4 neutropenia in two, grade 4 neutropenia and
febrile neutropenia in one, grade 4 neutropenia and grade 3
dyspnea in one), and this dose was acceptable. These results
are similar to those reported in another study.11 However,
amrubicin 40 mg/m2 induced severe toxicity in 57% of the
third-line chemotherapy patients (4/7: grade 4 neutropenia in
2, grade 4 neutropenia and febrile neutropenia in 1, grade 4
neutropenia, febrile neutropenia and grade 3 fatigue in one).
However, the rate of severe toxicity (14%: one of seven
patients with grade 4 neutropenia and febrile neutropenia) at
the lower dose (35 mg/m2) of amrubicin was acceptable
(Table 3).
The MST and 1-year survival rate in this study were 9.2
months and 33.3%, respectively. The results were much
better than in a recent phase II study that evaluated the
activity of topotecan against recurrent SCLC.17 In addition,
the results of our study were comparable with those of a
phase II study that evaluated the activity of amrubicin against
refractory or recurring SCLC.11 In conclusion, amrubicin is
an active agent for previously treated SCLC, and the recom-
mended doses in second-line and third-line settings are 40
mg/m2 on days 1 to 3 and 35 mg/m2 on days 1 to 3,
respectively. Because of the greater activity of the single-
agent amrubicin, further studies on amrubicin either as a
single agent or in combination with other agents, such as
cytotoxic or target-based agents, are warranted in previously
treated SCLC patients.
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TABLE 3. Response by Dose
No. of Patients PR SD PD RR (%)
Overall 27 8 8 11 29
Second-line: 40 mg/m2 13 6 3 4 46
Third-line: 40 mg/m2 7 1 3 3 14
Third-line: 35 mg/m2 7 1 2 4 14
Sensitive 7 3 3 1 42
Refractory 20 5 5 10 25
PR, partial response; SD, stable disease; PD, progressive disease; RR, relative risk.
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